

For a new future to transform patients' lives

Vivet Therapeutics is a clinical-stage biotech company developing novel gene therapy treatments for rare, inherited metabolic diseases. Vivet's lead program, VTX-801, is a novel investigational gene therapy for Wilson disease that is currently under clinical development in the GATEWAY — Phase 1/2 clinical study.